Cel­sius aims to cool down in­flam­ma­tion with new in­vestors and more phar­ma deals

Broad In­sti­tute spin­out Cel­sius Ther­a­peu­tics is turn­ing up the heat on the fi­nanc­ing front as it looks to ice the symp­toms of in­flam­ma­to­ry bow­el dis­ease.

The Cam­bridge, MA biotech has added $83 mil­lion in new fi­nanc­ing — a mix­ture of a Se­ries A ex­ten­sion and Se­ries B funds — to chase its vi­sion of pre­ci­sion ther­a­pies across au­toim­mune dis­eases and can­cer. The Third Rock- and GV-backed start­up, found­ed in 2018, brought in new in­vestors like Am­gen Ven­tures, Am­pli­tude Ven­tures and Fast Track Ini­tia­tive.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER